Nebulized Versus Intravenous Magnesium Sulfate in Treatment of Asthma Exacerbation
Efficacy of Nebulized Versus Intravenous Magnesium Sulfate in Treatment of Asthma Exacerbation
1 other identifier
observational
123
1 country
1
Brief Summary
A prospective study in Beni-Seuf University Hospital that was conducted on 123 adult patients with acute asthma exacerbations. Patients were classified into group (I): received IV magnesium sulfate, group (II): received nebulized magnesium sulfate, and group (III): control group. Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done for all patients before treatment, immediately after the treatment, "30", and "60" min after treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 30, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 22, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2020
CompletedFirst Submitted
Initial submission to the registry
May 26, 2023
CompletedFirst Posted
Study publicly available on registry
June 18, 2023
CompletedJune 18, 2023
June 1, 2023
1.1 years
May 26, 2023
June 8, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Improving pulmonary function tests as PEFR for asthmatic patients
Prevention of the progression asthma exacerbation for included subjects
13 monthes
Study Arms (3)
IV Magnesium Sulfate
Inhaled Magnesium Sulfate
Control group
Interventions
Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done
Eligibility Criteria
131 patients were included in the study.Eight subjects were excluded due to presence of heart failure or renal failure.
You may qualify if:
- adult patients between the ages of 18 and 50 years with acute attack of bronchial asthma
- From both sexes
- Normal Renal function
- Normal Cardiovascular function
You may not qualify if:
- Patients were younger than 18 years or older than 50 years.
- Patients suffered from chronic obstructive pulmonary disease
- Patidnts suffered from renal disorder
- Patients with heart failure.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Medicine Beni-suef university
Banī Suwayf, 62521, Egypt
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Clinical Pharmacy
Study Record Dates
First Submitted
May 26, 2023
First Posted
June 18, 2023
Study Start
October 30, 2018
Primary Completion
November 22, 2019
Study Completion
December 15, 2020
Last Updated
June 18, 2023
Record last verified: 2023-06
Data Sharing
- IPD Sharing
- Will not share